Michael King
Stock Analyst at EF Hutton
(0.86)
# 3,988
Out of 5,097 analysts
109
Total ratings
36.52%
Success rate
-11.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $18.49 | +3,415.41% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.65 | +201.37% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.33 | +2,306.02% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.91 | +3,486.39% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $15.32 | +1,205.48% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.67 | +1,139.92% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $779.36 | +10.60% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $46.19 | -48.04% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $3.51 | +4,629.34% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $15.97 | +162.99% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $407.73 | -25.44% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $9.70 | +1,095.88% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.14 | +100.39% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $45.20 | -46.90% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $0.67 | +1,799,540.07% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $50.33 | -8.60% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $24.95 | +284.77% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.66 | +5,339.71% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $39.34 | -21.20% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $852.04 | -95.77% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $18.49
Upside: +3,415.41%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.65
Upside: +201.37%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.33
Upside: +2,306.02%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.91
Upside: +3,486.39%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $15.32
Upside: +1,205.48%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.67
Upside: +1,139.92%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $779.36
Upside: +10.60%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $46.19
Upside: -48.04%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $3.51
Upside: +4,629.34%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $15.97
Upside: +162.99%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $407.73
Upside: -25.44%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $9.70
Upside: +1,095.88%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $5.14
Upside: +100.39%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $45.20
Upside: -46.90%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $0.67
Upside: +1,799,540.07%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $50.33
Upside: -8.60%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $24.95
Upside: +284.77%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.66
Upside: +5,339.71%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $39.34
Upside: -21.20%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $852.04
Upside: -95.77%